Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-20

Study Completion Date

2022-09-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obstructive sleep apnea (OSA) is increasingly recognized in patients with squamous cell carcinoma of the head and neck (SCCHN). The prevalence prior and after cancer therapy is not well understood. OSA is identified as a contributing factor for daytime somnolence and quality of life (QOL), yet treatment of OSA in the SCCHN population has not been studied. The investigators hope to identify the disease course of sleep apnea, risk factors for development, and impact on QOL with treatment of OSA in a population of patients with SCCHN.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer

NCT03875053

Locally Advanced Head and Neck Squamous Cell Carcinoma Metastatic Head and Neck Squamous Cell Carcinoma

WITHDRAWN NA

Innovative OSA Screening in Head and Neck Cancer Patients With the Apneal App

NCT06896448

Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Head and Neck Cancers

NOT_YET_RECRUITING NA

Obstructive Sleep Apnea Syndrome After Oropharyngeal Cancer Treatment

NCT02881723

Obstructive Sleep Apnea Syndrome Oropharyngeal Cancer

UNKNOWN NA

Obstructive Apnea in Patients Submitted to Partial Laryngectomy

NCT01157286

OBSTRUCTIVE SLEEP APNEA

UNKNOWN

Obstructive Sleep Apnea Syndrome In Patients Treated For Cancer Of The Upper Aerodigestive Tract

NCT04262453

Upper Aerodigestive Tract Neoplasms Obstructive Sleep Apnea-hypopnea Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will conduct a prospective cohort study of enrolled patients seen in initial consultation by our H\&N cancer surgeons and/or Radiation Oncologists either at AMC or HRH. Data collected from patients in the form of quality of life and sleep questionnaires and home sleep study (Alice Night One System by Phillips Respironics), as well as data from the electronic medical record will be coded into RedCap.

Blood collection for inflammatory biomarkers will occur during routine laboratory workup to avoid unnecessary phlebotomy whenever possible. Blood laboratory specimens of the inflammatory markers will be centrifuged to plasma and stored at -80C in freezers located on the Anschutz campus in Research Complex 2 on the 7th floor. Patients who require tracheostomy will be included in this study but will not have any sleep study time-point as indicated. Patients who are identified to have OSA will undergo counseling and treatment as per standard of care. CPAP compliance data will be collected every three months after initiation of OSA treatment.

Patient details including demographics, treatment information such as surgery, radiation, and chemotherapy, sleep and quality of life questionnaire data, pro-inflammatory cytokines, and sleep study results will collected. The RedCap database will be maintained by the PI, or their delegate of the present study, and all persons utilizing the RedCap database for purposes of entering data will be included on the Delegation of Authority.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea Squamous Cell Carcinoma of Head and Neck

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Research group

Sleep apnea testing will be performed with this group, in the form of quality of life and sleep questionnaires, home sleep study results, as well as information collected from their electronic medical record. The investigator will also obtain blood laboratory specimens to measure serum TNF-alpha and IL-6.

Group Type EXPERIMENTAL

Obstructive sleep apnea testing

Intervention Type DIAGNOSTIC_TEST

* Functional Outcomes of Sleep Questionnaire (FOSQ-10)
* European Organization for Research and Treatment of Cancer Head and Neck Survey (EORTC HN 35)
* Epworth Sleepiness Scale (ESS)
* Adult Comorbidity Evaluation (ACE 27)
* University of Washington Quality of Life Questionnaire (UW-QOL)
* Chronic Pain Assessment Questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Obstructive sleep apnea testing

* Functional Outcomes of Sleep Questionnaire (FOSQ-10)
* European Organization for Research and Treatment of Cancer Head and Neck Survey (EORTC HN 35)
* Epworth Sleepiness Scale (ESS)
* Adult Comorbidity Evaluation (ACE 27)
* University of Washington Quality of Life Questionnaire (UW-QOL)
* Chronic Pain Assessment Questionnaire

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects between the ages of 21 (inclusive) and 90 (inclusive). Anyone that is over 89 years old will be labeled as 89 in the data analysis.
2. Patients with an established relationship with the adult Otolaryngology and/or Radiation Oncology clinic at AMC or HRH.
3. Patients that present with a new diagnosis of oropharyngeal SCC who undergo radiation treatment, with or without chemotherapy.
4. Patients who may require trachesotomy will be included.
5. Stated willingness to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria

1. Under the age of 21 or over the age of 90.
2. Unwilling to sign the informed consent.
3. Unable or unwilling to participate in sleep studies.
4. Patients who have had a prior diagnosis of SCCa of the head and neck including nasopharynx, oral cavity, oropharynx, larynx and hypopharynx will be excluded. Patients with prior non-cutnaeous non-SCC tumors of the head and neck will also be excluded. Patients with prior skin cancer diagnoses will not be excluded.

Minimum Eligible Age

21 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No